Speech by Federal Chancellor Dr. Angela Merkel at the opening of the new research building of the Berlin Institute for Medical Systems Biology on February 26, 2019, in Berlin:

Germany Angela Merkel · Former Chancellor of Germany

26 February 2019 · Opening of the new research building of the Berlin Institute for Medical Systems Biology · Berlin Institute for Medical Systems Biology, Berlin, Germany

Context
Merkel addressed scientists and guests at the opening of the new BIMSB research building in Berlin on February 26, 2019.
Main themes
Medical systems biology, single-cell biology, gene regulation, organoids and disease modeling, artificial intelligence and machine learning in medicine, interdisciplinary research, data availability and anonymization, Alexander von Humboldt and universal scholarship, research funding and collaboration, pluripotent cell research, breakthroughs in biotechnology
Duration
~17 min
59th percentile
Words
2,072
59th percentile
Sentences
128
74th percentile
Readability
48
57th percentile
Grade
10.4
25th percentile
Syntax
2.85
28th percentile
Vocabulary
2.05
18th percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 27%27%
  • Ceremonial 25%25%
  • Technological 23%23%
  • Institutional 15%15%
  • Economic 8%8%
  • Geopolitical 2%2%
  • Environmental 0%0%
  • Not in focus 2%

128 sentences in 27 paragraphs

Dear Professor Lohse,

dear Professor Rajewsky,

dear State Secretary Krach and dear State Secretary Schütte,

ladies and gentlemen – I do not want to greet all the dignitaries; because if I forget someone, that would not be good –, above all: dear employees, there are clearly not 200 people here in the room. I also greet those who cannot be here today or have to work somewhere. But it is certainly a beautiful day. I am pleased about the invitation. And I am truly happy to be here for the opening of the Berlin Institute for Medical Systems Biology, BIMSB. I am very grateful for the opportunity I had to visit the institute with three young scientists and to get a small impression of what you have just presented again.

A new location here in the heart of Berlin. It is good that there are hospitals like Charité here, but it is also good that there are not only ministries and the chancellery in the vicinity, but also research institutions and universities. So this is a new location for you, where you can develop new ideas and apply new methods, but essentially pursue an old dream, perhaps the oldest dream of humanity, namely to live as long and as healthily as possible.

Since the beginning of modern medicine, scientists have been working to shed more light on the mystery of a long life. We can truly say – we just saw the charts – that we are increasingly understanding how a healthy organism functions and how diseases arise. But the book of life is still so sealed and encrypted that probably generations after you will still have plenty of opportunities to research it.

It is a platitude that with every gain in knowledge, our horizon naturally expands. But the beauty of research is that it continually presents new challenges. This is quite similar to politics: whenever a problem is solved, there are ten new ones waiting to be addressed. Therefore, you will of course continue to work intensively at this new place.

The central question you are pursuing – how does gene regulation occur in healthy and diseased cells? – is of course very exciting. I remember the end of my biology class when we had arrived at adenine and the like. When you see what can be done today experimentally, but also theoretically, it is truly fascinating. You are cultivating individualized disease models, so-called organoids, from reprogrammed skin cells of patients – especially from patients suffering from certain diseases. This allows the disease mechanism to be analyzed in individual cells. For me – I am only following this from a distance – it is one of the incredible things that you can revert differentiated cells back to pluripotent cells and then gain a comprehensive overview. It shows that evolution is taking place and that it can be traced in any temporal direction. I find that truly fascinating.

Research in single-cell biology was – I quote again what you had already projected on the wall – one of the breakthroughs of 2018. So judged the American scientific journal "Science." Now one could say: If "Science" says that, then there is of course no contradiction. I would just like to say that "Science" is also embedded in a larger world. I think you should not be ashamed if you occasionally publish in another journal. But the judgment of "Science" does carry a lot of weight. "Science" specifically highlighted the work at the Max Delbrück Center. BIMSB researchers were significantly involved in this pioneering achievement. That is truly something to be proud of.

We talk a lot about where we stand in connection with artificial intelligence. Here we have a very practical application. Machine learning helps to process and understand the data mountains of single-cell biology. I was able to see that as well. But we also need to discuss whether we have enough data. Data is the raw material for artificial intelligence. Especially in medicine, we need to ensure that there are enough anonymized – I emphasize this for the public – data available so that we can really make comparisons and see the patterns clearly.

This building exemplifies that top research in many areas is only conceivable beyond the boundaries of individual disciplines – such as between biotechnology, biochemistry, molecular biology, computational science, and medicine. How important it is to collaborate across disciplinary boundaries at BIMSB to overcome the limits of knowledge is very clear even to laypeople.

There is actually a very interesting development. This year we are thinking about the 250th anniversary of Alexander von Humboldt's birth. The Humboldts were perhaps among the last universal scholars. After that, things became incredibly differentiated. Today, however, we are moving back towards bringing different fields and disciplines closer together and thinking in various combinations again.

Dear Professor Rajewsky, BIMSB was founded in 2008 at your initiative at the Max Delbrück Center for Molecular Medicine. The federal government and the state of Berlin supported your institute early on; you just presented that. That it emerged from a pilot project within the federal program "Top Research and Innovation in the New States" also shows what has been possible in 30 years of German unity, which we will celebrate next year. It is good to remember that. Since 2012, BIMSB has been institutionally funded within the Max Delbrück Center. 16 research groups, 250 researchers – I think your example also reflects the strength of the Max Delbrück Center as a whole. As a member of the Helmholtz Association, it is one of the leading biomedical research centers in the world.

Scientific excellence and internationality go hand in hand here. That is why international support for young talent is also highly valued. I find that very important, namely not only to collaborate across research areas but also across the boundaries of institutions and countries. That you coordinate the LifeTime consortium from Berlin, with the involvement of the Helmholtz Association and together with partners in France, is also very, very good news.

I greet the guests from France. Although I will not be traveling to Paris tomorrow solely because of you, I will also report on my experience today there. Because especially in the area of scientific cooperation, we have a lot planned. In the Aachen Treaty, we explicitly stated that we want to collaborate in the field of artificial intelligence and form a joint network. This fits in very well here. The LifeTime consortium is supported by more than 120 researchers from 53 research institutions in 18 countries. This also shows what global collaboration means and that multilateral cooperation still works very well in some areas.

The federal government has a special concern to advance health research. Since 2009, we have established the German Centers for Health Research. Right at the beginning of this legislative period, we adopted a new framework program. It defines the guidelines according to which medical research in Germany is to be funded over the next ten years. I believe a hallmark of recent years has become that we work reliably, that we work sustainably. This has greatly benefited the scientific location of Germany and enhanced its attractiveness.

I should also warmly greet you from the Minister of Research, who is thankfully in my constituency today, namely at Wendelstein 7-X, where possible new forms of future energy supply are to be advanced – by the way, also an international project like yours here.

In particular, we also want to ensure that medical progress reaches patients even faster; you have also emphasized this here. This is also important because people read and hear about certain things and then naturally ask: When can I participate in that? Therefore, translation, that is, the transfer of research results into medical applications, must be consistently further developed. That is good. We just need to ensure that the relevant committees allow that quickly. This is currently a challenge for the Minister of Health.

To advance translation, we must also make boundaries more permeable – boundaries between academic and industrial research, between experimental and theoretical research, and between research and care. We therefore want to further expand the existing German Centers for Health Research on common diseases. I was able to convince myself in Bonn of what is being achieved there.

We also want to significantly strengthen university medicine together with the states, which is the central driver of translation – Professor Frei will be pleased to hear these words. However, if you have ever experienced a meeting of research and health ministers from the states and the federal government, you know what still needs to be done in terms of translation between two categories of ministries. It is certainly very interesting how some interact with others and believe that they are each the center. But mutual respect is equally important.

In recent years, there have been remarkable advances, especially in cancer research. We certainly want to build on that. Here, too, research progress must quickly reach practice. Therefore, we have launched a national overall strategy for tumor control with the "National Decade Against Cancer." We want closer collaboration and networking – from top research to medical treatment. Teamwork is also crucial to better understand tumor diseases and to bring reliable therapies into application. You are also involved in early detection.

For medical progress in general, technological progress can be utilized. This is also something we must repeatedly communicate in society, namely that seemingly very distant things can suddenly yield individual benefits. It is clear that especially the digital transformation opens up completely new possibilities. – We have already been able to see how data scientists work here. – Therefore, we as the federal government want to promote the training of data scientists; and especially in the life sciences. We support professorships and junior research groups in bioinformatics and medical informatics. And we have adopted a strategy for the promotion of artificial intelligence as a federal government. That is also very necessary.

I am a little concerned whether we are developing enough expertise in these areas in Germany. It is very important that we encourage young people who are deciding on fields of study to consider this area. Because as nice as it is to have Israeli and other guests – we also have incredible future opportunities for our own people here. There is a global competition for smart minds in this field. We now want to fill one hundred additional AI professorships at German universities to promote young talent as quickly as possible.

In the future, we will provide around 2.5 billion euros per year for health research. There is no doubt that this is a profitable investment. This also means that we are an attractive location. We are challenged in the competition for knowledge and skills because the world is not standing still. We know this in light of China, Korea, Japan, and the United States of America. Therefore, we need strong university research and a strong non-university research landscape. We have had ongoing discussions about the fact that universities are essentially under the authority of the states and that non-university research institutions are under mixed responsibility. We have decided that the federal government will take over the annual increases in funding for non-university research institutions. In addition, we have also reluctantly taken over BAföG benefits. This has given the states more leeway. Some have used this, others less so, but I do not want to elaborate on that here; that was not an attack on Berlin.

We are therefore trying to bring consistency and long-term planning into things. We are currently experiencing in the discussions with the Minister of Finance, where Mr. Schütte has just been, that the time of annually increasing tax revenues is, for the moment, over. This will also be the test for us to see whether science and research will really remain our focus. In any case, I will advocate for this, because we have also made long-term commitments here. And these are commitments that will help determine our future. That must be made very clear.

Therefore, be proud of your beautiful gem. Where the Permanent Representation of the Federal Republic of Germany in the GDR used to be, a place of the future has now emerged. And that is a beautiful sign. Enjoy it by spending as many hours here as possible, without neglecting your families too much.

Thank you very much.